Ignite Creation Date:
2024-05-05 @ 11:48 AM
Last Modification Date:
2024-10-26 @ 9:13 AM
Study NCT ID:
NCT00137761
Status:
COMPLETED
Last Update Posted:
2009-11-01
First Post:
2005-08-26
Brief Title:
Docetaxel in Combination With Iressa in Previously Treated Patients With Pancreatic Cancer
Sponsor:
Dana-Farber Cancer Institute
Organization:
Dana-Farber Cancer Institute
Study Overview
Official Title:
A Phase II Study of Docetaxel in Combination With ZD 1839 IRESSA in Previously Treated Patients With Metastatic Pancreatic Cancer
Status:
COMPLETED
Status Verified Date:
2009-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to find out what activity the combination of docetaxel and Iressa have against metastatic pancreatic cancer
Detailed Description:
Iressa will be taken orally once daily without interruption Docetaxel will be administered intravenously once weekly for two out of every three weeks Patients will also receive dexamethasone the night prior morning of and the evening after docetaxel treatment to help prevent an allergic reaction
Every week that chemotherapy is given blood tests and vital signs will be taken
After the first 6 weeks of therapy a CT scan or other radiological procedure will be done to assess the progress of the disease If the cancer is responding to the treatment and no unacceptable side effects have occured treatment with Iressa and docetaxel will continue
CT scans or other radiological procedure will be performed at week 12 and every 9 weeks thereafter to monitor the progress of the disease
Every week that chemotherapy is given blood tests and vital signs will be taken
After the first 6 weeks of therapy a CT scan or other radiological procedure will be done to assess the progress of the disease If the cancer is responding to the treatment and no unacceptable side effects have occured treatment with Iressa and docetaxel will continue
CT scans or other radiological procedure will be performed at week 12 and every 9 weeks thereafter to monitor the progress of the disease
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None